Ask AI

Targeting BCMA in Early Relapsed/Refractory Myeloma: Translating New Clinical Evidence Into Managed Care Strategies

Gain expert insights into the rationale for targeting BCMA in early relapsed/refractory multiple myeloma and the latest evidence-based strategies for monitoring and managing related toxicities to improve patient outcomes through a certified on-demand webcast with accompanying downloadable slides and ClinicalThought commentary.

Share

Program Content

Events

Activities

RR MM Overview and BCMA Directed CAR T Therapy
Targeting BCMA in Early R/R Myeloma: Overview & CAR T-Cell Therapy
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 13, 2026

BCMA Directed BsAB and ADC in RR MM
Targeting BCMA in Early R/R Myeloma: Bispecific Antibodies and Antibody Drug Conjugates
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 13, 2026

Care management considerations for RR MM
Targeting BCMA in Early R/R Myeloma: Considerations for Care Management
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: April 13, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Supporters

This educational activity is supported by independent medical education grants from GSK and Johnson & Johnson.

GSK

Johnson & Johnson